Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Restructuring Costs (2022 - 2025)

Spero Therapeutics (SPRO) has disclosed Restructuring Costs for 3 consecutive years, with $83000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Restructuring Costs changed N/A year-over-year to $83000.0, compared with a TTM value of $1.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $877000.0, changed N/A over the prior year.
  • Restructuring Costs was $83000.0 for Q2 2025 at Spero Therapeutics, down from $175000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $11.8 million in Q2 2022 and bottomed at -$8.6 million in Q4 2022.
  • Average Restructuring Costs over 3 years is $710333.3, with a median of $129000.0 recorded in 2025.